Recent Research Funding

We receive funding from a variety of sources that recognize the value of our high-impact research.

Richard Browne, PhD

  • Contract Renewal: Clinical Pharmacology Quality Assurance and Quality Control. Richard Browne (Co-Investigator), Gene Morse (Principal Investigator). NIH/National Institute of Allergy and Infectious Disease. $12,754,564. 3/1/2015-2/1/2022.
  • The metabolomics of neurofilaments, neurodegeneration nexus in Multiple Sclerosis progression. Richard Browne (Co-Investigator). DOD. 7/1/2020-6/1/2023.
  • Effect of Complex Mixtures of Oxidative Stress and Cognition in Children. Richard Browne (Co-Investigator). NIH/NIEHS. 9/1/2020-6/1/2025.

Stephen Koury, BS MT (ASCP), MS, PhD

  • Western New York in Genetics and Health Care Partnership. Stephen Koury (Co-Principal Investigator). National Institutes of Health. $1,268,962. 6/1/2014-5/1/2019.

Jinwoo Park, PhD

  • Mapping Heterogeneous Dopamine Signaling in Subregions of the Olfactory Tubercle and Its Effect on Psychostimulant-induced Behaviors. Jinwoo Park (Principal Investigator). NIH/NIDA. $408,034. 7/1/2018-6/1/2020.
  • Noradrenergic Modulation of Dopaminergic Neuronal Functions. Jinwoo Park (Principal Investigator). Whitehall Foundation. $225,000. 9/1/2017-8/1/2020.

Daesung Shin, PhD

  • Selective galactosylceramidase ablation to study the pathogenesis of Krabbe leukodystrophy. Daesung Shin (Principal Investigator). NIH-NINDS. $1,395,624. 12/1/2019-11/1/2023.
  • The peripheral nervous system: A window into Krabbe disease. Daesung Shin (Co-Investigator). NIH-NINDS. $2,129,163. 2/1/2019-1/1/2024.